Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Classificação em ações #25851
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Preço da ação
$15.31
Última sincronização: 2024-02-29
Valor de mercado
$45.70M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Icosavax, Inc. (ICVX)

Categoria

Rácio P/B de Icosavax, Inc. (ICVX)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Icosavax, Inc., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Icosavax, Inc. de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US